In both studies.

Clinical data in simeprevir for treatment of hepatitis C individuals to be presented at EASL meeting Medivir Abdominal today announces that data will be presented on the investigational protease inhibitor simeprevir for the treatment of genotype 1 hepatitis C patients. In both studies, 50 % of sufferers receiving pegylated interferon and ribavirin by itself achieved SVR12 http://levitraenligne.net/levitra-avis-et-commentaire.html . The info will be presented this week at The International Liver Congress 2013 of the European Association for the Study of the Liver in Amsterdam, The Netherlands. The QUEST-1 and QUEST-2 data will also be discussed in an official EASL press meeting on April 24 at 11:00 a.m.

levitraenligne.net

The outcomes of a randomized trial in 45 individuals with primary invasive breast cancers showed that the drug –which is currently used to treat arthritis and other painful conditions- – clearly induced an anti-tumor response at the molecular level. ‘That is exciting because it means that a medication already used to take care of other diseases may be efficient in the adjuvant treatment of breast cancer as well,’ said lead researcher Juergen Veeck, from Maastricht University Medical Centre in The Netherlands. Celecoxib is a known member of a class of medicines referred to as selective COX-2 inhibitors. These drugs directly target COX-2, an enzyme responsible for pain and inflammation.